To compare the short-term results of the efficacy and safety of dexamethasone intravitreal implant (DEX), ranibizumab (RAN), and intravitreal triamcinolone acetonide (IVTA) in macular edema secondary to branch retinal vein occlusion (BRVO).
Methods
One eye each of 32 patients who were treated with intravitreal injections for macular edema secondary to BRVO was studied. This retrospective study included 3 groups. The patients received DEX in group 1 (n = 11), RAN in group 2 (n = 11), and IVTA in group 3 (n = 10). Data were collected before and after the injections at the first and third months. Best-corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP) were analyzed statistically.
Results
The median duration of the follow-up was 3.0 months in overall groups. The BCVA increased significantly in all groups (p = 0.018, p = 0.034, p = 0.014, respectively). The CMT increased significantly in groups 1 and 3 (p = 0.02, p<0.001, respectively), but not in group 2 (p = 0.14). The IOP increased significantly in groups 1 and 3 (p = 0.05, p<0.001, respectively). Antiglaucomatous treatment was required only in group 3. Cataract developed in 2 patients (20%) in group 3 and surgery was required.
Conclusions
Although RAN was the safest among the 3 agents, DEX and IVTA reduced CMT more than RAN, while significant improvement was achieved in BCVA in all groups. All 3 agents can be effectively used in the treatment of macular edema due to BRVO.
WeinbergDDodwellDGFernSAAnatomy of arteriovenous crossings in branch retinal vein occlusion. Am J Ophthalmol1990109298–302.
2.
KolarPRisk factors for central and branch retinal vein occlusion: a meta-analysis of published clinical data. J Ophthalmol20142014724780.
3.
WongTYMitchellPThe eye in hypertension [Review] [erratum. 2007;369:2078]. Lancet2007369425–35.
4.
WongTYLarsenEKKleinRCardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities & Cardiovascular Health studies. Ophthalmology2005112540–7.
5.
KleinRKleinBEMossSEMeuerSMThe epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc200098133–41 discussion 141-3.
6.
The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol198498271–82.
7.
GewailyDGreenbergPBIntravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst Rev20091CD007324.
8.
KreplerKErgunESacuSIntravitreal triamcinolone acetonide in patients with macular oedema due to branch retinal vein occlusion: a pilot study. Acta Ophthalmol Scand200583600–4.
9.
CampochiaroPAHeierJSFeinerL; BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology20101171102–12.
10.
HeierJSCampochiaroPAYauLRanibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology2012119802–9.
11.
HallerJABandelloFBelfortRJr; OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology20101171134–46.
12.
HallerJABandelloFBelfortRJr; Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology20111182453–60.
13.
Group TBVOS; The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol198498271–82.
Group TCVOS. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology19951021425–33.
16.
AdamisAPMillerJWBernalMTIncreased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol1994118445–50.
17.
KanedaSMiyazakiDSasakiSMultivariate analyses of inflammatory cytokines in eyes with branch retinal vein occlusion: relationships to bevacizumab treatment. Invest Ophthalmol Vis Sci2011522982–8.
18.
Ki-IYArimuraNNodaYStromal-derived factor-1 and inflammatory cytokines in retinal vein occlusion. Curr Eye Res2007321065–72.
19.
NomaHFunatsuHHarinoSMimuraTEguchiSHoriSVitreous inflammatory factors in macular edema with central retinal vein occlusion. Jpn J Ophthalmol201155248–55.
20.
NomaHFunatsuHMimuraTShimadaKIncrease of aqueous inflammatory factors in macular edema with branch retinal vein occlusion: a case control study. J Inflamm2010744.
21.
OkunukiYUsuiYKataiNRelation of intraocular concentrations of inflammatory factors and improvement of macular edema after vitrectomy in branch retinal vein occlusion. Am J Ophthalmol2011151610–6.
22.
NabihMPeymanGATawakolMENaguibKToxicity of high-dose intravitreal dexamethasone. Int Ophthalmol199115233–5.
23.
CaponeAJrSingerMADodwellDGEfficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study). Retina201434342–51.
24.
MayerWJWolfAKerntMTwelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion. Eye201327816–22.
25.
BrownDMCampochiaroPASinghRP; CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology20101171124–33.
26.
BrownDMCampochiaroPABhisitkulRBSustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology20111181594–602.
27.
CampochiaroPABrownDMAwhCCSustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology20111182041–9.
28.
BakriSJSnyderMRReidJMPulidoJSEzzatMKSinghRJPharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology20071142179–82.
29.
EpsteinDLAlgverePVvon WendtGSeregardSKvantaABenefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology20121192587–91.
30.
ThachABYauLHoangCTuomiLTime to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials. Ophthalmology20141211059–66.
31.
ChangLKSpaideRFKlancnikJMLonger-term outcomes of a prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Retina201131821–8.
32.
PucheNGlacetAMimounGZourdaniACoscasGSoubraneGIntravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes. Acta Ophthalmol201290357–61.
33.
NauckMKarakiulakisGPerruchoudAPPapakonstantinouERothMCorticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol1998341309–15.
34.
JonasJBAkkoyunIKamppeterBKreissigIDegenringRFBranch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye20051965–71.
35.
GuthoffRMeigenTHennemannKSchraderWComparison of bevacizumab and triamcinolone for treatment of macular edema secondary to branch retinal vein occlusion in a pair-matched analysis. Ophthalmologica2010224319–24.
36.
TaoYHouJJiangYRLiXXJonasJBIntravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Eye201024810–5.
37.
JonasJBDegenringRFKreissigIAkkoyunIKamppeterBAIntraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology2005112593–8.
38.
ScottIUIpMSVanVeldhuisenPC; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol20091271115–28.
